Source:http://linkedlifedata.com/resource/pubmed/id/16652052
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2006-5-2
|
| pubmed:abstractText |
Patients infected with HIV-1 with more than 1000 HIV-1 RNA copies/mL, who were genotyped within 3 months before starting stavudine and treated for at least 3 months with a stable stavudine-containing highly active antiretroviral therapy, were selected from our database to identify the determinants of response to stavudine. Nonresponse was defined as a failure to achieve HIV-1 RNA level of less than 400 copies/mL or a reduction of more than 2 log10 by week 12. Univariate logistic analysis was used to elicit the failure-associated reverse transcriptase mutations (scored 1 to develop a genotype score). Eighty-one patients were eligible for the analysis, including 75 (93%) who previously received zidovudine. Thirty-five (43%) were nonresponders. Univariate logistic analysis revealed the following failure-associated mutations: 41L (P = 0.0001), 44D (P = 0.02), 118I (P = 0.0006), 184V (P = 0.04), 210W (P = 0.0004), and 215Y (P = 0.002) for a median stavudine score of 2. Failure was observed in 7 (18.9%) of 37 patients with a score less than 2, compared with 28 (63.6%) of 44 patients with a score of 2 or greater (P < 0.0001). The multivariable analysis showed that the 118I mutation (P = 0.04) was the only independent genotypic predictor of failing on a stavudine- containing highly active antiretroviral therapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1525-4135
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
41
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
447-52
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16652052-Adult,
pubmed-meshheading:16652052-Anti-HIV Agents,
pubmed-meshheading:16652052-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:16652052-Drug Resistance, Viral,
pubmed-meshheading:16652052-Female,
pubmed-meshheading:16652052-Genes, pol,
pubmed-meshheading:16652052-HIV Infections,
pubmed-meshheading:16652052-HIV Reverse Transcriptase,
pubmed-meshheading:16652052-HIV-1,
pubmed-meshheading:16652052-Humans,
pubmed-meshheading:16652052-Logistic Models,
pubmed-meshheading:16652052-Male,
pubmed-meshheading:16652052-Middle Aged,
pubmed-meshheading:16652052-Mutation, Missense,
pubmed-meshheading:16652052-RNA, Viral,
pubmed-meshheading:16652052-Salvage Therapy,
pubmed-meshheading:16652052-Sequence Analysis, DNA,
pubmed-meshheading:16652052-Statistics as Topic,
pubmed-meshheading:16652052-Stavudine,
pubmed-meshheading:16652052-Treatment Failure,
pubmed-meshheading:16652052-Viral Load
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients.
|
| pubmed:affiliation |
Clinic of Infectious Diseases, Vita-Salute San Raffaele University, Italy. gianotti@hsr.it
|
| pubmed:publicationType |
Journal Article
|